PharmaFocus Today – Page 40 – media

intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received positive news regarding BD ...
- Source: drugdu
- 103
- October 12, 2024
14.1 billion, Johnson&Johnson announces big move

On October 9th, Johnson&Johnson announced plans to invest over $2 billion (approximately RMB 14.1 billion) in Wilson, North Carolina to build an advanced biopharmaceutical manufacturing facility to support its growing portfolio of biologic therapy products in oncology, immunology, and neuroscience. It is reported that this measure is in line with Johnson&Johnson’s broader strategy of submitting or launching over 70 new therapies and product expansions by the end of the next decade. The new facility will be equipped with cutting-edge technology, which will not only enhance global production capacity, but also provide approximately 420 high skilled full-time positions for the local area. The project will begin construction in the first half of 2025. In August of this year, in order to strengthen its position in the cardiovascular field, Johnson&Johnson announced the acquisition of V-Wave, a company specializing in heart failure treatment technology. Prior to this, Johnson&Johnson acquired for approximately $13.1 billion ...
- Source: drugdu
- 95
- October 12, 2024
Dental laser equipment leader, bankrupt and acquired

On October 9, 2024, Biolase, which dominates the global dental laser equipment market, announced that it has signed an agreement to sell most of its assets to competitor Sonendo for $14 million. Biolase, a leading dental laser expert in the world, has long been committed to the research and manufacturing of fully functional lasers, with a global laser market share of 70%. But due to long-term losses, the stock price remained low, and it was delisted from NASDAQ in June this year, and declared bankruptcy on October 1st. The buyer of this acquisition case, Sonendo, is a dental giant dedicated to root canal treatment equipment. Its subsidiary sued Biolase in 2023 for a patent dispute and demanded compensation of no less than $59 million. This acquisition not only marks the end of an era for giant Biolase, but also declares the end of the aforementioned patent dispute. 01. The world’s ...
- Source: drugdu
- 104
- October 12, 2024
A new star in the 10 billion respiratory market, a new generation of ICS drugs is heavily recruited!

Asthma/COPD is a common respiratory disease in my country, with more than 53 million asthma patients. The prevalence rate in adults is 4.2%, and the prevalence rate in children is 3.07%, with about 7.6 million children. According to statistics, about 30% of urban children with asthma are not diagnosed in time, and more than 20% of children with asthma are not well controlled. There is a huge unmet clinical demand. According to the guideline data, the prevalence of COPD in adults aged 20 and above in my country is 8.6%, and that in adults aged 40 and above is as high as 13.7%. It is estimated that the number of COPD patients in my country is nearly 100 million. According to the full-terminal data of the hospital market of Yaorongyun, although the asthma/COPD drug market has fluctuated due to external factors such as the epidemic and centralized procurement, it has ...
- Source: drugdu
- 102
- October 12, 2024
Twinings Biopharmaceuticals, Lingrui, Hisun…

As of the first three quarters, there were 9 pharmaceutical stocks with a market value of 100 billion yuan, with Mindray Medical firmly in the top spot and Hengrui Medicine returning to a market value of 300 billion yuan. In terms of quantity, there were 4 more stocks compared with the first half of the year, with Aier Eye Hospital, Yunnan Baiyao, United Imaging Healthcare, and Wantai Biopharma returning to the 100 billion yuan market value echelon. Among the TOP20, 15 stocks have positive growth, with Hengrui Medicine, BeiGene, Yunnan Baiyao, Shanghai Pharmaceuticals, China Resources Sanjiu, Baili Tianheng and 10 other stocks growing at a rate of more than 10%; while in the first half of the year, only 6 stocks had positive growth, with 4 other stocks growing at a rate of more than 10%, including Shanghai Pharmaceuticals and China Resources Sanjiu. Mindray Medical has firmly established itself as ...
- Source: drugdu
- 93
- October 12, 2024
New president of Beckman takes office

Recently, according to the official website of Beckman Coulter Life Sciences, Danaher subsidiary Beckman Coulter Life Sciences (hereinafter referred to as Beckman) announced the appointment of Joe Fox as president, effective immediately. It is understood that Joe Fox is a veteran of Danaher. He served as president of Danaher subsidiary Sciex, and before becoming president, he held several leadership positions in the company, including senior vice president of global sales and services. In 13 years, Joe Fox has held positions with increasing responsibilities until he became president recently. Before joining Sciex, Joe Fox held technical and commercial positions at Bruker and Shimadzu, and Joe Fox also holds a degree in biochemistry from the University of Delaware and a doctorate in chemistry from Johns Hopkins University. After taking office, Joe Fox will lead a global team of more than 3,300 employees to promote product and service innovation to provide solutions in ...
- Source: drugdu
- 106
- October 12, 2024
A major pharmaceutical province issued a document to dig deep into medical corruption

In May this year, the National Health Commission and 14 other departments issued the “Notice on Printing and Distributing the Key Points for Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sale and Medical Services in 2024”, which includes 5 parts and 15 items. The local level has also successively issued the key points for correcting unhealthy trends in 2024. Judging from the above-mentioned “Notice” issued by Shanghai, the key points for Shanghai’s corrective work in 2024 are basically consistent with the national documents, and some new content has also been added, totaling 5 parts and 18 items. The “Notice” clearly states that the city’s centralized rectification of corruption in the pharmaceutical field and the centralized rectification of unhealthy trends and corruption around the masses should be carried out in a coordinated manner, and the construction of systems in the field of pharmaceutical purchase and sale should be ...
- Source: drugdu
- 124
- October 12, 2024
Drugdu.com Shines at CPhI Milan 2024

▲October 2024, CPhI Milan On October 10, 2024, the highly anticipated CPhI Milan event concluded in Italy, leaving behind a lasting impression. Drugdu.com, a global leader in cross-border pharmaceutical B2B platforms, stood out with its innovative digital solutions and accurate buyer-supplier matching services, garnering widespread attention from the global pharmaceutical community. ▲Drugdu.com at the CPhI Milan show in October 2024 Platform Highlights: Smart Cross-Border Trade Services At the event, Drugdu.com demonstrated its leading smart supply-demand matching feature, allowing buyers to effortlessly post procurement needs and swiftly connect with high-quality global suppliers. The platform’s real-time, efficient negotiations boosted transaction success, with many participants leveraging its capabilities to finalize collaborations during the exhibition. Additionally, Drugdu.com provided VIP members with customized promotion strategies, offering exclusive brand exposure and diverse inquiry channels to help businesses expand their global market presence. Advancing Digital Pharmaceutical Trade Beyond being a platform, Drugdu.com is committed to advancing the digitalization ...
- Source: drugdu
- 87
- October 11, 2024
intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

October 11, 2024 09:03 Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received ...
- Source: drugdu
- 127
- October 11, 2024
Beckman’s new president takes office

Recently, according to the official website of Beckman Coulter Life Sciences, a subsidiary of Danaher, Beckman Coulter Life Sciences announced the appointment of Joe Fox as President, effective immediately. Following the promotion of Chen Xiaoxiao, former General Manager of Beckman Clinical Diagnostics China, to President of Danaher China Medical Diagnostic Platform in the first half of the year, Beckman has once again announced personnel changes. It is understood that Joe Fox is a veteran of Danaher and has served as the president of Danaher’s subsidiary, Sciex. Prior to becoming president, he held multiple leadership positions at the company, including Senior Vice President of Global Sales and Service. Over the course of 13 years, Joe Fox’s responsibilities have increased, until he recently became president. Prior to joining Sciex, Joe Fox held technical and business positions at Bruker and Shimadzu, and also holds a Bachelor of Science degree in Biochemistry from the ...
- Source: drugdu
- 93
- October 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.